Tetra Bio-Pharma Inc. (OTCMKTS:TBPMF) has announced the signing of a co-development agreement with MAKScientific. According to the agreement, Tatra will get access to patented new molecules having CB1 and CB2 antagonists and agonist properties.
Tetra enters partnership agreement with MAKScientific
This comes after the company gave additional information on the CAUMZTM drug development program after it had announced a Type B meeting with the FDA. The agreement secures new patented drug candidates for development by the company.
MAKScientific is a popular endocannabinoid R&D development company, and it has a pipeline of drugs that target CB1 and CB2 receptors and other associated targets in the endocannabinoid system. According to the agreement, the company will develop new molecules that Tetra will screen for efficacy in various indications such as pain, cancer, inflammation, and also any other potential indications that will interest Tetra.
Tetra and Panag Pharma CSO Melanie Kelly indicated that the partnership agreement with MAKScientific presents huge potential for Panag Pharma to expand its research as well as advance novel drug molecules to the clinic. Kelly added that Professor Alexandros Makriyannis’, the founder of MAKScientific, expertise in drug development in the CBD space, has been important in understanding the interaction of drugs with the endocrine system.
Tetra’s CAUMZTM-kit to treat cancer cachexia
The company’s CAUMZTM program will be important in cancer cachexia treatment, and to ensure minimal time to market, it will target patients with refractory malignant and incurable cancer. Tetra has designed CAUMZTM to improve the quality of life and prolong the survival of patients. The provision of these benefits to cancer cachexia patients will be a vital contribution to the well-being and care of the patients.
The company is expecting to receive Fast Track Designation for accelerated review of CAUMZTM, which treats serious medical conditions with unmet medical needs. FDA has agreed that the target population treated with CAUMZTM has serious medical needs with substantial morbidity. CAUMZTM is similar to QIXLEEFTM, and the FDA said that it will be eligible for waivers representing savings of $5 million in the short-term for its initial marketing applications.
Business intelligence from Akerna Corp (NASDAQ:KERN) Says Liquor Sales are Up 10% Year-over-Year
Post Views: 388 Liquor sales are up 10% year-over-year according to business intelligence from Akerna Corp (NASDAQ:KERN). Red wine took...
Pyxis Tankers Inc. (NASDAQ:PXS) Announce Q1 2020 Financial Results Amid COVID-19 Uncertainties
Post Views: 227 Pyxis tankers Inc. (NASDAQ:PXS) has announced its unaudited financial results for the quarter that ended March 31,...
Innovative Industrial Properties Inc (NYSE:IIPR) Enters Into a Lease Amendment Agreement with Green Leaf
Post Views: 249 With pot being legalized in many countries, the market is likely to get even bigger. As a...
Liberty Leaf Holdings Ltd (OTCMKTS:LIBFD) Takes Over Nova Mentis Biotech Corp And Add Synergies To Its Cannabis Assets In The Wellness And Health Sector
Post Views: 253 Liberty Leaf Holdings Ltd (OTCMKTS:LIBFD) gained access to the psilocybin by acquiring Nova Mentis Biotech Corp. The...
Aleafia Health Inc (OTCMKTS:ALEAF) Begins Cultivation At Its Entire Niagara Facility And Provides Consistent Supplies for Health: Settles Disputes With Aphria
Post Views: 357 Aleafia Health Inc (OTCMKTS:ALEAF) will commence cultivation operations at its whole Niagara facility. It obtained a license...
Pure Capital Calls For Shareholders Meeting of Therapix Biosciences Ltd (NASDAQ:TRPX): Demands For Dismissal Of Board Members
Post Views: 296 Pure Capital called for an emergency meeting of investors of Therapix Biosciences Ltd (NASDAQ:TRPX) to discuss actions...